Clinical trial · Observational
Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer. Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pyruvate kinase isoform M2 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer patient
- interventionNames
- Other: Pyruvate kinase isoform M2
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Any cancer patient with pleural effusion that is being drained through an indwelling chest-tube in an inpatient ward. Exclusion Criteria: * Patient with a pleural effusion who does not have proven cancer or whose pleural effusion is not known to be malignant.
References
Publications (2)
- BACKGROUNDElia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Eur J Cardiothorac Surg. 2008 Apr;33(4):723-7. doi: 10.1016/j.ejcts.2008.01.014. Epub 2008 Feb 7. PMID 18261916
- BACKGROUNDMazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 2007;(4):99-124. doi: 10.1007/2789_2008_091. PMID 18811055